High yield bond markets see issuance slow as borrowers and investors step back from new deals due to macroeconomic headwinds and geopolitical uncertainty
Elevated inflation and interest rate hikes in Europe and the US,...more
Following a year of healthy activity, M&A deals in the pipeline are set to sustain leveraged finance issuance in the pharmaceutical, medical and biotech sector in the months ahead -
Lender appetite for exposure to the...more
2/9/2022
/ Acquisitions ,
Biotechnology ,
Borrowers ,
Capital Markets ,
Coronavirus/COVID-19 ,
Environmental Social & Governance (ESG) ,
Financial Services Industry ,
Global Market ,
Healthcare ,
High Yield Bonds ,
Lenders ,
Leveraged Loans ,
Mergers ,
Pharmaceutical Industry
High yield issuance across major global markets made steady gains in the first nine months of 2021 in most regions, as investor appetite for yield supported stable activity through the year.
In the US, high yield issuance...more
Although US high yield bond issuance cooled somewhat in Q3 2020, it still hit record highs, while European activity remained on an upward trend.
High yield bond markets in the United States and Western and Southern Europe...more